

6758 99 MAY 25 A9:17

U.S. REGULATORY AFFAIRS

May 24, 1999

Dockets Management Branch, HFA-305
Food and Drug Administration
5600 Fishers Lane, Room 1061
Rockville, MD 20852

RE: Docket No. 99D-0484

Dear Sir or Madam,

Wyeth-Ayerst Laboratories, a Division of American Home Products Corporation, respectfully submits comments to Docket No. 99D-0484 regarding the draft guidance for industry entitled "Accelerated Approval Products- Submission of Promotional Materials."

Wyeth-Ayerst Laboratories is a major research-oriented pharmaceutical company with leading products in the areas of women's health care, cardiovascular disease therapies, central nervous system drugs, anti-inflammatory agents, vaccines and generic pharmaceuticals. American Home Products Corporation is one of the world's largest research-based pharmaceutical and health care products companies, and is a leading developer, manufacturer and marketer of prescription drugs and over-the-counter medications.

The aforementioned draft guidance provides procedures that sponsors can use to submit promotional materials to the Agency for products that are approved under the accelerated approval regulations [21 CFR 314.550 and 601.45]. The draft procedures provide reasonable direction in this regard. However, we believe that fast track products are not necessarily subject to all provisions of accelerated approval regulations. Section 506(b)(2)(B) of the Federal Food, Drug and Cosmetic Act (the Act) states:

"Approval of a fast track product under this subsection **may** (emphasis added) be subject to the requirements-...that the sponsor submit copies of all promotional materials related to the fast track product during the preapproval review period and, following approval and for such period thereafter as the Secretary determines to be appropriate, at least 30 days prior to dissemination of the materials."

99D-0484

C4

The use of the verb “may” in this subsection leaves an option for the requirement for preapproval promotional materials of fast track products, as opposed to the use of a stronger verb such as “shall,” which is used in other subsections of section 506 to clearly denote a requirement.¹ Many fast track products undergo a full development program, with meaningful clinical endpoints that are not surrogate markers for the respective disease. Further study of the product to verify and describe clinical benefit is not needed. This is a situation analogous to product approval under “usual” circumstances, in which a requirement for routine pre-approval of promotional materials is not deemed necessary by the Agency. Accordingly, we propose that the draft guidance note the following as footnote 2, to properly reflect language in section 506(b) of the Act:


“Sponsors whose drug or biological product is in a fast track program that is eligible for approval under section 506(b) of the Federal Food, Drug and Cosmetic Act may also be subject to 314.50 and 601.45 and can use these procedures.”

In addition, there are other categories of products that can be approved under rapid conditions but not necessarily under the accelerated approval regulations, namely, products designated for priority review, and products developed under the auspices of Subpart E regulations [21 CFR 312.80-88].² Again, many of these products undergo a full development program, with meaningful clinical endpoints that are not surrogate markers for the respective disease. Further study of the product to verify and describe clinical benefit is not needed, abating the need for routine pre-approval of promotional materials. We propose that the guidance explicitly state that it is not applicable to products designated for priority review, or products developed under the auspices of Subpart E regulations, unless they are specifically approved under accelerated approval regulations. Footnote 2 of the guidance may be an appropriate place to mention this.

Wyeth-Ayerst Laboratories appreciates the opportunity to comment on the draft guidance, “Accelerated Approval Products- Submission of Promotional Materials.” We look forward to the issuance of this guidance in final form.

Sincerely,

WYETH-AYERST LABORATORIES

A handwritten signature in black ink that reads "Diane Mittrione". The signature is written in a cursive, flowing style.

Diane Mittrione
Senior Director
U.S. Regulatory Affairs

¹ See, for example, section 506(a)(3), “...within 60 calendar days....the Secretary shall determine whether the drug....meets the criteria described...”.

² Drugs intended to treat life-threatening and severely-debilitating illnesses.

Express
Shipping
Label

Align top of FedEx PowerShip Label here.

FedEx

Express
Shipping
Label

☐ For use by PowerShip
Customers only



312

UBFW 11/97
PART 151953 Rev. 7/97
©1994-97 Federal Express Corporation

Form I.D. No. 0205

Sender's FedEx Account Number

20116/01000
1426-3156-3

4856551

8030 1553 0537

FedEx

8030 1553 0537

FedEx Tracking Number — PULL UP PURPLE TAB

From Diane Mitrione

Ship Date 5/24/99

To (If Hold for)

ip Codes.)

WYETH/AYERST LABS
150 RADNOR CHESTER RD 1ST FL
ST DAVIDS PA 19087-5252

Dockets Management Branch (HFA-305)
Food and Drug Administration
5630 Fishers Lane
Room 1061
Rockville, MD 20852


Release No.

Reference Info

1012305

Services		FedEx Priority Overnight		FedEx Standard Overnight		FedEx 2Day		FedEx First Overnight		FedEx Express Saver		FedEx Overnight Freight		FedEx 2Day Freight		FedEx Expre. Saver Freight	
WEIGHT	DECLARED VALUE	<input checked="" type="checkbox"/> FedEx Letter	<input type="checkbox"/> FedEx Box	<input type="checkbox"/> FedEx Letter	<input type="checkbox"/> FedEx Box	<input type="checkbox"/> FedEx Letter	<input type="checkbox"/> FedEx Box	<input type="checkbox"/> FedEx Letter	<input type="checkbox"/> FedEx Box	<input type="checkbox"/> FedEx Letter	<input type="checkbox"/> FedEx Box	<input type="checkbox"/> FedEx Letter	<input type="checkbox"/> FedEx Box	<input type="checkbox"/> FedEx Letter	<input type="checkbox"/> FedEx Box	<input type="checkbox"/> FedEx Letter	<input type="checkbox"/> FedEx Box
		<input type="checkbox"/> FedEx Pak	<input type="checkbox"/> FedEx Tube	<input type="checkbox"/> FedEx Pak	<input type="checkbox"/> FedEx Tube	<input type="checkbox"/> FedEx Pak	<input type="checkbox"/> FedEx Tube	<input type="checkbox"/> FedEx Pak	<input type="checkbox"/> FedEx Tube	<input type="checkbox"/> FedEx Pak	<input type="checkbox"/> FedEx Tube	<input type="checkbox"/> FedEx Pak	<input type="checkbox"/> FedEx Tube	<input type="checkbox"/> FedEx Pak	<input type="checkbox"/> FedEx Tube	<input type="checkbox"/> FedEx Pak	<input type="checkbox"/> FedEx Tube
		<input type="checkbox"/> Other Pkg.		<input type="checkbox"/> Other Pkg.		<input type="checkbox"/> Other Pkg.		<input type="checkbox"/> Other Pkg.		<input type="checkbox"/> Other Pkg.		<input type="checkbox"/> Other Pkg.		<input type="checkbox"/> Other Pkg.		<input type="checkbox"/> Other Pkg.	

☐ Hold at FedEx Location - Weekday ☐ Hold at FedEx Location - Saturday ☐ Deliver Saturday ☐ Dangerous Goods ☐ Dlc



20852 -MD-US

ZMEDGR

IAD RR

cad # 0051346 24MAY99
TRK# 8030 1553 0537 FORM 25MAY99

PRIORITY OVERNIGHT TUE

8030 1553 0537 FedEx
8030 1553 0537
REF: 1012305

SEE ADDRESS LABEL ON PACKAGE FOR
THIS SHIPMENT TO MD 20852

150 DOMESTIC MAIL ROOM
WYETH/AYERST LABS
150 RADNOR CHESTER RD FLR 1
ST DAVID PA 19087-5252
(610)902-1495
SHIP DATE: 24MAY99
RCN # 142631563
ACTUAL WGT: 1 LBS SCALE

In Time
DELIVER